Pronota N.V. develops diagnostics using a technology platform that uniquely mines for novel low-abundance protein biomarkers in blood.
The lead program of Pronota is in pre-eclampsia, a condition of late pregnancy that can severely impact the health of mother and child.
Portfolio: MedSciences Capital II B.V.
Current product development stage: clinical validation.
Merged into MyCartis N.V.
